Brief: Allovir Announces Positive Final Results In Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation

Kalaris Therapeutics

11/12/2022 24:00

Dec 10 (Reuters) - Allovir Inc  ALVR.O :
    * ALLOVIR ANNOUNCES POSITIVE FINAL RESULTS IN PHASE 2
POSOLEUCEL
MULTI-VIRUS PREVENTION STUDY IN ORAL PRESENTATION AT THE 64TH
ASH ANNUAL MEETING AND EXPOSITION
    * 88% PATIENTS REMAINED FREE OF CLINICALLY SIGNIFICANT
INFECTIONS
THROUGH WEEK 14 PRIMARY ENDPOINT
    * 12% PATIENTS HAD SIGNIFICANT INFECTIONS DESPITE 85%
PATIENTS
REACTIVATING 1 OR MORE OF 6 POTENTIALLY DEVASTATING VIRUSES
    * ALLOVIR - BIOMARKER DATA SUPPORT CLINICAL RESULTS BY
DEMONSTRATING EXPANSION OF FUNCTIONAL VIRUS-SPECIFIC T CELLS
COINCIDENT WITH VIRAL LOAD DECLINES
    * ENROLLMENT PROGRESSING IN PHASE 3 POSOLEUCEL MULTI-VIRUS
PREVENTION REGISTRATIONAL TRIAL IN U.S., EUROPE AND ASIA

Source text for Eikon:  ID:nBwc3bpgva 
Further company coverage:  ALVR.O 
 ((Reuters.Briefs@thomsonreuters.com;))